Phase 2Active, not recruitingAge-related condition
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
A Phase 2, Single Arm, Multicenter Study to Evaluate the Pharmacodynamics and Safety of Re-Treatment With ALXN2220 in Patients With Transthyretin Amyloid Cardiomyopathy
- Sponsor
- Neurimmune AG (Industry)
- Enrolment
- 35 planned
- Conditions
- Amyloid Transthyretin Cardiomyopathy
- Interventions
- ALXN2220
- Ages
- adults, older adults
- Registry
- NCT07213583, CTIS2025-520506-35-00
Full record on ClinicalTrials.gov
From the registry
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
Primary outcomes
- Change from Baseline to Week 48 in ECV measured by cMRI
- Change from Baseline to Week 48 in Heart Retention/Whole Body Retention measured by scintigraphy
History
Primary completion expected
Last registry update
Registered
Started